Aurelia study ovarian
WebNov 10, 2015 · Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial WebPfisterer J, Weber B, Reuss A, et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer ...
Aurelia study ovarian
Did you know?
WebApr 1, 2024 · This study may contribute to developing a new combination regimen for the treatment of ovarian cancer. Trial registration ... Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomised phase III trial. Obstetrical & Gynecological Survey. … WebDec 1, 2024 · The addition of bevacizumab should be considered based on the results of the AURELIA study (NCT00976911) [155], ... in a predominantly platinum-resistant recurrent ovarian cancer [192]. In this study, it was observed that treatment produced an immunostimulatory environment, characterised by enhancement of IFNγ and …
WebMar 17, 2014 · Purpose In platinum-resistant ovarian cancer (OC), single-agent chemotherapy is standard. Bevacizumab is active alone and in combination. AURELIA is … WebThe FDA wound up approving the first ovarian cancer indication in 2014 based on a 3.4-month PFS benefit demonstrated in the Phase III AURELIA study, plus positive results in secondary endpoints like response rate and duration of response. (Also see "FDA clears Roche/Genentech to market Avastin in ovarian cancer" - Scrip, 14 Nov, 2014.)
WebMar 11, 2024 · The glimmer of hope was the phase 3 AURELIA study [NCT00976911], where bevacizumab [Avastin] was added to chemotherapy, and there was a statistically significant prolongation of PFS. WebApr 13, 2024 · The purpose of this study was to retrospectively assess the pattern, compliance, efficacy and safety of bevacizumab in Chinese ovarian cancer patients. We …
Webaurelia: 1. a female given name: from Latin Aurelianus, a family name.
WebApr 13, 2024 · The purpose of this study was to retrospectively assess the pattern, compliance, efficacy and safety of bevacizumab in Chinese ovarian cancer patients. We reviewed the clinicopathological data of patients with histologically confirmed epithelial ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma, who were … how old is sam from scream 5WebMay 20, 2012 · In the AURELIA study, patients with platinum-resistant ovarian cancer with one or two prior lines of systemic therapy (platinum refractory excluded) were … how old is sam golbach 2022WebJun 8, 2024 · Patients and methods. Data from AURELIA (n = 326), a randomized trial of chemotherapy with or without bevacizumab, were used to identify baseline QoL domains … how old is sam golbach girlfriendWebSep 19, 2024 · Median OS after ICI was 18.3 months (95 percent CI, 11.8–22.7) for our heavily pretreated population of patients. This OS was promising compared to inferior … how old is sam hazenWebSep 5, 2024 · The phase I/II TOPACIO/KEYNOTE-162 study (NCT02657889) evaluated the combination of niraparib (Zejula) plus pembrolizumab (Keytruda) in patients with recurrent ovarian cancer. Findings from the ... mercy springfield mo cnoWebSep 15, 2009 · AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer. ... Pujade-Lauraine E. Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy. Ann Oncol. 2024 Aug 1;28(8):1849-1855. doi: 10.1093/annonc/mdx229. ... mercy springfield mo himWebPatients received single-agent chemotherapy (paclitaxel, PLD, or topotecan) alone or in combination with bevacizumab until disease progression or unacceptable toxicity (the AURELIA study). In this study, a significant benefit was observed in PFS in patients receiving bevacizumab plus chemotherapy (6.7 months) than in those receiving ... mercy springfield mo egd